摘要
目的:探讨中药复方治疗初治继发型肺结核合并肝损害患者的临床疗效和安全性。方法:选取2011年4月—2012年4月在我院治疗的90例合并肝损害初治继发型肺结核患者为研究对象,应用随机数字表法将符合本研究纳入标准和排除标准的患者分为对照组和实验组,每组各45例,对照组患者给予西利宾胺护肝治疗,而实验组则给予中药复方护肝治疗,两组患者其他治疗措施完全相同。观察两组患者的临床疗效和安全性。结果:实验组患者治疗总有效率均明显高于对照组患者的,有显著性差异(P<0.05),而实验组患者中断化疗人数、调整化疗方案人数和药物不良反应发生率明显低于对照组患者的,有显著性差异(P<0.05)。结论:中药复方治疗继发型肺结核合并肝损害的临床疗效显著,疗效优于西利宾胺,安全性高,不良反应少。
Objective ：To investigate the clinical efficacy and safety of hairstyle tuberculosis patients with hepatic lesion by Chinese herbal compound prescription. Methods ：The clinical data of ninety hairstyle tuberculosis patients with hepatic lesion who were in our hospital from Aril 2011 to April 2012 were collected, they were divided into the control group （cases = 45 ） and the experimental group （ cases = 45 ） by random number table. The patients in the control group were given silybin meglumine, but the patients in the experimental group were given Chinese herbal compound prescription. The other treatment measures for patients of two groups were exactly the same; the clinical efficacy and safety of the two groups were compared. Results ： The total efficiency rate of the experimental group were significantly higher than that in the con- trol group （P 〈 0.05 ）. But the number of interrupting chemotherapy and adjusting chemotherapy regimens of the experimental group were significantly lower than that in the control group （P 〈 0. 05 ）. Conclusion：The clinical efficacy of Chinese herbal compound prescription is superior to single silybin meglumine treatment of hairstyle tuberculosis patients with hepatic lesion. It has low recurrence and adverse reaction rate.
出处
《中华中医药学刊》
CAS
2013年第6期1248-1250,共3页
Chinese Archives of Traditional Chinese Medicine
基金
国家自然科学基金资助项目(81071318)
关键词
中药复方
继发型肺结核
肝损害
临床疗效
安全性
Chinese herbal compound prescription
Silybin meglumine
Hepatic lesion
clinical efficacy
safety
